Clinical Trials Logo

Diabetic Nephropathies clinical trials

View clinical trials related to Diabetic Nephropathies.

Filter by:
  • Active, not recruiting  
  • Page 1 ·  Next »

NCT ID: NCT06176599 Active, not recruiting - Clinical trials for Diabetic Kidney Disease

Clinical Study on the Treatment of Diabetic Kidney Disease With Shenxiao Yuning Decoction With Syndrome of Qi and Yin Deficiency and Blood Stasis

SXYNT
Start date: September 1, 2022
Phase: N/A
Study type: Interventional

To explore the therapeutic effect of Shenxiao Yuning Decoction on albuminuria and the improvement of traditional Chinese medicine syndrome in patients with stage III diabetic kidney disease with Qi and Yin deficiency and blood stasis syndrome.

NCT ID: NCT06123871 Active, not recruiting - Clinical trials for Diabetic Nephropathy

Expression Analysis of Urinary Exosome in Type 2 Diabetic Kidney Disease and Evaluation of Its Clinical Diagnostic Value

Start date: June 1, 2020
Phase:
Study type: Observational

Expression analysis of urinary exosome miR-136-5p in type 2 diabetic nephropathy and evaluation of its clinical diagnostic value

NCT ID: NCT06097351 Active, not recruiting - Clinical trials for Diabetic Nephropathy

Expression Analysis of Urinary Exosome in Type 2 Diabetic Nephropathy and Evaluation of Its Clinical Diagnostic Value

Start date: June 1, 2020
Phase:
Study type: Observational

Expression analysis of urinary exosome miR-142-3p in type 2 diabetic nephropathy and evaluation of its clinical diagnostic value

NCT ID: NCT05656963 Active, not recruiting - Thromboembolism Clinical Trials

The Influencing Factors and Mechanism of High Incidence of Thrombotic Events in Patients With MN and DKD

Start date: September 1, 2021
Phase:
Study type: Observational

Influence factors and preliminary mechanism of high incidence of thrombotic events in patients with idiopathic membranous nephropathy and diabetes kidney disease

NCT ID: NCT05487755 Active, not recruiting - Clinical trials for Diabetic Nephropathy Type 2

Investigational and Comparative Study in the Management of Diabetic Nephropathy

Start date: January 1, 2022
Phase: Phase 3
Study type: Interventional

The objective of this study is to investigate and compare the safety and efficacy of selective (PDE5) enzyme inhibitor; tadalafil and non selective (PDE) inhibitor; pentoxifylline in diabetic nephropathy to improve glucose metabolism, lipid profile and decrease albuminuria.

NCT ID: NCT05198284 Active, not recruiting - Clinical trials for Chronic Kidney Diseases

Prospective Decision Impact Clinical Utility Trial of KidneyIntelX

Start date: November 1, 2021
Phase:
Study type: Observational

The clinical utility trial is designed to evaluate how the results of KidneyIntelX test / platform impacts on the clinical management of type 2 diabetes patients identified as increased risk for rapid kidney function decline within 5-years.

NCT ID: NCT04960514 Active, not recruiting - Clinical trials for Diabetic Kidney Disease

Prospective Decision Impact Trial of KidneyIntelX

Start date: November 22, 2021
Phase:
Study type: Observational

The current trial is designed to evaluate how the results of KidneyIntelX test / platform impacts on the clinical management of type 2 diabetes patients identified as increased risk for rapid kidney function decline within 5-years.

NCT ID: NCT04869761 Active, not recruiting - Clinical trials for Diabetes Mellitus, Type 2

Stem Cell Therapy for Chronic Kidney Disease

Start date: October 7, 2021
Phase: Phase 1
Study type: Interventional

The purpose of this study is to assess the safety and tolerability of allogeneic mesenchymal stem / stromal cell therapy in individuals with chronic kidney disease.

NCT ID: NCT04589351 Active, not recruiting - Clinical trials for Diabetes Mellitus, Type 2

Kidney Fat in Type 2 Diabetes and the Effects of Ezetimibe

DiaKidZ
Start date: October 1, 2020
Phase: Phase 3
Study type: Interventional

In this study, we seek to explore the importance of fat accumulation in the kidneys in relation to diabetic kidney disease (DKD). To do this, we conduct an intervention trial in individuals with type 2 diabetes (T2D) and DKD where we investigate whether the inhibition of intestinal cholesterol absorption with ezetimibe affects albuminuria (a strong risk factor for diabetic complications) and kidney fat accumulation. At the same time and to confirm that kidney fat accumulation is, in fact, abnormal in T2D and DKD, we conduct a cross-sectional study in which we compare kidney fat accumulation in participants at baseline from the intervention trial with a group of individuals with T2D and no DKD and a group of healthy individuals.

NCT ID: NCT04573920 Active, not recruiting - Clinical trials for Diabetic Kidney Disease

Atrasentan in Patients With Proteinuric Glomerular Diseases

AFFINITY
Start date: February 1, 2021
Phase: Phase 2
Study type: Interventional

The AFFINITY Study is a phase 2, open-label, basket study to evaluate the efficacy and safety of atrasentan in patients with proteinuric glomerular disease who are at risk of progressive loss of renal function.